Last reviewed · How we verify
Lumason
At a glance
| Generic name | Lumason |
|---|---|
| Also known as | SonoVue, Infusion Administration, sulfur hexafluoride, sulfur hexafluoride lipid-type A microspheres |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions ( 5.1 )] . Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions ( 5.1 )] . Assess all patients for the presence of any condition that precludes administration [see Contraindications ( 4 )]
Common side effects
- Headache
- Nausea
- Dysgeusia
- Injection site pain
- Feeling Hot
- Chest discomfort
- Chest pain
- Dizziness
- Injection Site Warmth
Serious adverse events
- Anaphylaxis
- Anaphylactic shock
- Hypersensitivity-type rash
- Presyncope
- Arrhythmias
- Hypertensive episodes
- Bronchospasm
- Dyspnea
- Angioedema
- Death
Key clinical trials
- Lumason® Infusion vs. Bolus Administrations (PHASE3)
- CEUS Evaluation of Hydrocephalus in Neonates and Infants (PHASE2)
- Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors (PHASE2)
- Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation (PHASE2)
- Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency (PHASE1)
- Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses (PHASE1)
- Effectiveness of Contrast-Enhanced Ultrasound (PHASE4)
- Contrast-Enhanced Ultrasound for Kidney Transplant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumason CI brief — competitive landscape report
- Lumason updates RSS · CI watch RSS
- Mayo Clinic portfolio CI